Capricor Therapeutics, Inc. (NASDAQ:CAPR) Given Average Rating of “Hold” by Analysts

Capricor Therapeutics, Inc. (NASDAQ:CAPR) has received a consensus recommendation of “Hold” from the eleven ratings firms that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, nine have assigned a hold recommendation and one has assigned a buy recommendation to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $29.15.

A number of research analysts have issued reports on CAPR shares. B. Riley Financial cut Capricor Therapeutics from a “buy” rating to a “neutral” rating and set a $10.00 price objective for the company. in a research note on Monday, July 27th. Weiss Ratings restated a “sell (d-)” rating on shares of Capricor Therapeutics in a report on Monday, June 15th. Cantor Fitzgerald raised Capricor Therapeutics from a “neutral” rating to an “overweight” rating in a research report on Friday. JonesTrading cut shares of Capricor Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, July 31st. Finally, Roth Capital downgraded shares of Capricor Therapeutics from a “buy” rating to a “neutral” rating and set a $7.00 price objective on the stock. in a research report on Monday, July 27th.

Insider Activity

In other news, CFO Anthony Bergmann sold 24,100 shares of the company’s stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $30.38, for a total value of $732,158.00. Following the transaction, the chief financial officer owned 11,223 shares in the company, valued at approximately $340,954.74. This represents a 68.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Insiders have sold a total of 25,000 shares of company stock valued at $759,158 in the last 90 days. Corporate insiders own 9.20% of the company’s stock.

Institutional Investors Weigh In On Capricor Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. Russell Investments Group Ltd. raised its holdings in Capricor Therapeutics by 122.2% in the 3rd quarter. Russell Investments Group Ltd. now owns 5,066 shares of the biotechnology company’s stock worth $37,000 after acquiring an additional 2,786 shares during the last quarter. ACT Capital Management LLC purchased a new stake in Capricor Therapeutics during the 4th quarter valued at $43,000. KBC Group NV bought a new stake in shares of Capricor Therapeutics in the 1st quarter worth $44,000. Tower Research Capital LLC TRC increased its holdings in shares of Capricor Therapeutics by 280.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,748 shares of the biotechnology company’s stock worth $67,000 after purchasing an additional 4,976 shares in the last quarter. Finally, Regal Investment Advisors LLC purchased a new stake in shares of Capricor Therapeutics during the third quarter valued at $92,000. Institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Stock Performance

Shares of NASDAQ CAPR opened at $7.45 on Tuesday. Capricor Therapeutics has a fifty-two week low of $2.96 and a fifty-two week high of $40.37. The company has a 50 day simple moving average of $17.81 and a two-hundred day simple moving average of $25.28. The company has a market capitalization of $431.43 million, a price-to-earnings ratio of -3.04 and a beta of 0.54.

Capricor Therapeutics (NASDAQ:CAPR) last issued its quarterly earnings results on Friday, August 14th. The biotechnology company reported ($0.70) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.11). On average, analysts forecast that Capricor Therapeutics will post -1.62 earnings per share for the current fiscal year.

Key Capricor Therapeutics News

Here are the key news stories impacting Capricor Therapeutics this week:

• Positive Sentiment: Capricor shares recently rallied after CEO comments addressing scrutiny of deramiocel and its regulatory outlook helped restore some investor confidence. The rebound may also have attracted short covering and speculative buying. Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers
• Neutral Sentiment: Multiple law firms reiterated that investors who purchased CAPR securities between December 17, 2025, and July 26, 2026, may seek lead-plaintiff status in a securities class action. The stated deadline is generally September 28, 2026, although one notice cites September 29. These announcements largely repeat existing litigation information rather than represent a new court ruling. Deadline Alert: Capricor Therapeutics Shareholders
• Negative Sentiment: The litigation notices allege that Capricor and certain executives made material misstatements or omissions concerning the statistical analysis plan, FDA compliance, and clinical prospects for its lead candidates. One notice links the allegations to an approximately $15.08 per-share decline following FDA briefing documents on the HOPE-3 trial, while another characterizes the prior decline as roughly 64%. The allegations have not been proven in court. CAPR Investor Alert: Securities Class Action Notice
• Negative Sentiment: Capricor’s recent quarterly loss exceeded analyst expectations, adding pressure to a stock whose valuation depends heavily on successful clinical development and regulatory progress. The repeated securities-fraud announcements increase reputational, legal, and uncertainty risks even as the shares remain well below their longer-term moving averages.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.